How dangerous are Donor Travels?

Slides:



Advertisements
Similar presentations
Purpose (You may click to go to the specific section or proceed through the presentation) Briefly review West Nile virus (WNV) ecology and epidemiology.
Advertisements

FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.
Vector-Borne Diseases of Public Health Importance Dawn M. Wesson Tulane University New Orleans, Louisiana.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
EU Parliament Office for Science and Technology- AVIESAN Work shop Brussels, 19 June 2012 Arboviral diseases and the threats for Europe Herve Zeller Emerging.
Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
EU and Wider Neighborhood Ukraine. EU and Wider Neighborhood Health Gap Main problem –premature adult morbidity and mortality Economic issue –loss of.
Managing the risk of vector borne diseases in adaptation measures Luciana Sinisi, Italy Chair Task Force Extreme Weather Events
Dengue Transfusion Risk Model Lyle R. Petersen, MD, MPH Brad Biggerstaff, PhD Division of Vector-Borne Diseases Centers for Disease Control and Prevention.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Current standards, donor safety, and blood supply
Dengue Virus and Its Risk to the U.S. Blood Supply
Tarrant County Public Health North Texas Regional Laboratory Six Years of West Nile Virus in Tarrant County, Texas Guy C. Dixon, Ph.D.
An important message to blood donors Please read this BEFORE you donate blood.
Pearlean Day, Ph.D student in Public Health Walden University PUBH Dr. Robert Marino Summer 2010.
DR. M MOHAMMED ARIF. ASSOCIATE PROFESSOR. CONSULTANT VIROLOGIST. HEAD OF THE VIROLOGY UNIT. Arboviruses.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
For more information, visit : or contact: Summary PROMOVAX is a 3-year EU-funded project.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Ecdc.europa.eu Tommi Asikainen, Tubingen, 22 October 2008 European Centre for Disease Prevention and Control FUTURE DISEASE CHALLENGES IN EUROPE – where.
Adapting to climate change Jonathan Suk 30 June 2010.
Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
S The European Up-Front Risk Assessment Tool (EUFRAT) The European Up-Front Risk Assessment Tool (EUFRAT) (EUFRAT)
Proposed algorithm for approval of human TSE tests in Europe.
Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Test Review Tips Community Health Assessment #1 Topics: Environmental Health Epidemiology & Communicable Disease.
2010 HIV/AIDS surveillance in Europe European Centre for Disease Prevention and Control, Stockholm WHO Regional Office for Europe, Copenhagen.
Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,
Risk assessment: The Safety of Blood Products presented by Dr. Thomas R. Kreil Baxter BioScience on behalf of the PPTA Pathogen Safety Steering Committee.
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.
Lecture 8 Estimation and Hypothesis Testing for Two Population Parameters.
Preventing Transmission of Chagas Disease in the U.S. Blood Supply: A Cost Effectiveness Analysis of Testing the Blood Bank Donations Danielle Doughman.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
1 Recent Global Development of Two Major Porcine Diseases - African Swine Fever and Porcine Epidemic Diarrhea - Dr Tomoko ISHIBASHI Deputy Regional Representative.
Global Insect Repellent Market By Manufacturers, Countries, Type And Application, Forecast To 2022 Global Insect Repellent Market By Manufacturers, Countries,
Outbreak Investigation
Zika.
ZIKA CASES (1/15 -9/7/16) USA- 2,964 total Travel associated 2,920
By: DR.Abeer Omran Consultant pediatric infectious disease
And how the spread Diseases
A new evaluation of the risk of transfusion-transmitted HIV prevented by a 12-month deferral before donation for men who have sex with men Josiane Pillonel,
One Book One Northwestern Book Group Discussion
Zika Virus Update CAPT Thomas Weiser, MD, MPH Medical Epidemiologist
Royal Thai Army Roles of mosquito vectors, bats, and swine in the epidemiology of emerging and re-emerging infectious diseases Akina Sukasem, 2LT Kanokporn.
Mosquito-borne diseases
Copyright © 2017 American Academy of Pediatrics.
Vector-borne diseases
Utah Zika investigation, July 2016
Paper by Zou, L. , S. N. Miller and E. T
International Union against Sexually Transmitted Infections
Strategies to incorporate pharmacoeconomics into pharmacotherapy
Immunization of travelers against japanese encephalitis Dr Catherine Goujon Centre médical de.
Zika Virus in Pregnancy
Clinical Manifestations and Epidemiology
Zika Virus Pathogenic Viral Infection
Controlling the risk of Chikungunya
Paper by Zou, L. , S. N. Miller and E. T
Brief overview of HIV among MSM in the EU/EEA
Enhanced malaria diagnosis capacity in camps hosting migrants/ refugees in Greece, Agis Terzidis Paediatrician, Vice president of Hellenic.
HEPATITIS C BY MBBSPPT.COM
West Nile Virus & Eastern Equine Encephalitis
ImmunoWELL Zika Virus Serology.
Prof A Marm Kilpatrick, PhD, Prof Sarah E Randolph, PhD  The Lancet 
Cases of travel-acquired dengue fever in Denmark 2001–2009
Fig. 6.9.
Presentation transcript:

How dangerous are Donor Travels? A Flaviviridae-based Risk Assessment Model M Caballero, C Niederhauser, N Andina, U Piazza, K Rotzetter, H Baumer, A Stadler, P Gowland, and S Fontana Blood Transfusion Service of the Swiss Red Cross, Berne

Flaviviridae and WNV: Definitions Primarily spread through arthropod vectors (mainly ticks and mosquitoes) The family gets its name from Yellow Fever virus, because of its propensity to cause jaundice in victims. Flaviviridae have linear, single-stranded RNA genomes. Virus particles are enveloped and spherical, about 40–60 nm in diameter. Flaviviridae challenging the safety of blood transfusion in the next years include for example: Dengue fever, West Nile encephalitis, Tick-borne encephalitis, Japanese encephalitis. West Nile Virus

Situation in Europa Increasing Flavivirus infection rates like WNV and Dengue in the general population has led to a potential increased risk of contaminated blood. Frequent blood donor travel activities and environmental changes have increased the risk of mosquito-transmitted human flaviviridae infections in Europe. Currently the most European countries rely on the ECDC definition of affected area for the implementation of safety measures, without taking into account their effect on blood supply and infection risk for patients. Definition of affected area: “At least one human case detected (i.e. probable or confirmed human case according to EU case definition).” (Commission Decision of 28/IV/2008)

The problem with the affected area The definition is independent from the dimension and the population of the area, although different areas may represent very different risks  no evaluation of the effective infectious risk The trigger for the implementation of precautionary measures (donor deferral, donor testing) is independent from the number of donors visiting the area  no evaluation of the risk on blood supply 2010 – 2013 several European countries reported single WNV cases (although >100 WNV affected persons per confirmed case are assumed)  the implemenation of precautionary measures may be arbitrary

Evolution of WNV reported cases in Europe

Evolution of WNV reported cases in Europe

Evolution of WNV reported cases in Europe

Evolution of WNV reported cases in Europe

Aims To build the fundament for a risk-effectiveness approach in taking precautionary decisions related to donor travel abroad. This by: developing a model to evaluate the effect of deferral policies on the infection risk of donors traveling to risk countries, collecting data on donors traveling abroad and putting them in the model, applying this model to West Nile Virus (WNV), a currently very relevant flavivirus infection in European blood transfusion medicine.

Methods Between 1 July – 30 November 2013 all blood donors were asked for travels abroad during the last month. A simple excel-based tool for risk calculation was developed. It incorporated disease specific variables, epidemiological data in the risk country, information about donors traveling abroad, and the number of blood donations performed in our region during the WNV season 2013 (1 July – 30 November). The effect of a one month deferral recommendation on the contamination risk of blood with WNV for affected countries publishing epidemiological data was calculated.

Model assumptions Mean asymptomatic infectivity 5.6 days Duration of epidemic: 150 days reported cases per country = number of confirmed cases reported by ECDC proportion of reported symptomatic cases = 30% the symptomatic cases length of stay 7 days (based on a control donor sample) N (blood donations) in our region during the epidemic period 39’293 traveling donors per country = effective numbers in 2013 Risk of infected donation applies to a donor donating within 30 days after returning from an endemic country The risk of an infected transfusion applies to a delivered component, considering the number of donors who donate within 30 days after travel and the total number of donations

Model assumptions Disease specific assumptions specific for one disease, the data are found in the current medical literature a: asymptomatic cases: 79% Proportion of asymptomatic cases of the disease under study (%/100) b: symptomatic cases: 21% Proportion of symptomatic cases of the disease under study (%/100) c: viraemia/bacteraemia among asymptomatic cases: 6.3 days Mean duration of viraemia/bacteraemia among asymptomatic cases of the disease under study (days) d: duration of asymptomatic viraemia/bacteraemia among symptomatic cases: 3.0 days Mean duration of asymptomatic viraemia / bacteraemia among symptomatic cases of the disease under study (days) Country specific variables specific for the country of interest e: duration of an epidemic: 150 days Duration of an epidemic of a disease in the country under study (days) g: cases detected during the epidemic period Number of cases detected during the epidemic period (n) h: population affected Population affected by the epidemic in the country or region (n inhabitants of the region)

Model calculations j: Mean duration of the asymptomatic infectivity in an infected case (blood donor) (days) j = [(a.c) + (b.d)]/100 k: Number of infected (asymptomatic and symptomatic) cases (n): k = [g+g(a/b)]/f f: corrector factor: which proportion of cases are documented in this country (%/100) m: attack rate in the country population under study m = k/h n: infection risk for blood donors visiting an affected country n = m(s/e) r: risk that an infected blood was donate during viremia period r= n(j/30) u: Number of blood donations during the considered time interval u t: risk that under all blood donations donated in a defined time interval – epidemics duration or month – one is infected t = (r.v)/u v = number of donors who traveled in an affected country in the given time interval v

Risk that the infected donor donates Risk of infected transfusion Results for WNV in coutries reporting to ECDC (number of confirmed cases known ) Country Confirmed cases (n) Traveling donors (n) Attack rate in country (x10-6) Risk that the infected donor donates Risk of infected transfusion (x10-9) Greece 58 140 86 0.75 2.66 Italy 69 1010 18 0.16 4.02 Serbia 200 7 436 3.81 0.68 Hungary 6 23 10 0.08 0.05 Romania 22 16 0.14 0.04 Bosnia Herz. 3 12 0.11 0.02 Israel 28 13 59 0.51 0.17 USA 2374 103 120 1.05 2.75 Canada 108 38 50 0.44 0.42 Low risk country, high donor numbers: low risk donor, high risk for patient  deferral useful but high impact on supply  threshold for WNV NAT? High risk country, low donor numbers: high risk donor, (rel.) high risk for patient  deferral useful and low impact on supply  deferral ok Low risk country and low donor numbers: low risk donor and patient  deferral less useful but low impact on supply  deferral or no measures?

Conclusions and future prospects The calculated risks of donors and patients acquiring a WNV infection are variable but are very low. This considering that the loss of virus infectivity during manufacturing and storage was not taken into account. This model allows comparing the effects of preventive measures on blood supply and on WNV infection risk, from both the perspective of blood banks and hospitals, who are involved in taking risk-adapted decisions. The model can be adapted to other transfusion-transmitted infections associated with travels abroad.

Conclusions and future prospects The monitoring of donors traveling abroad and of the deferrals will be repeated in 2014, in order to consolidate the data A long-range monitoring system will be introduced, in order to be able to evaluate the risks of every measure for both blood supply and transfusion transmidded infections Based on a risk analysis Switzerland already set the threshold for the introduction of WNV NAT in case of WNV outbreak in the country at 5 confirmed cases per month per affected area (base for comparison: cost-effectiveness on the HBV NAT) We suggest that in the future the evaluation of preventive measures for donors traveling in affected area will not onlyapply the definition of affected area, but will consider these risks.

Aknowledgements Merci viumau